YP2A.F · BioLineRx Ltd

-

Please sign in to comment on YP2A.F

1 Comment

Admin

4 years ago

BioLineRx Ltd is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

BioLineRx Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 21.5% to $-12M since the same quarter in the previous year.

Finally, its free cash flow grew by 0.3% to $-5M since the same quarter in the previous year.

Based on the above factors, BioLineRx Ltd gets an overall score of 3/5.

Exchange	F
CurrencyCode	EUR
ISIN	US09071M2052
Sector	Healthcare
Industry	Biotechnology

Beta	0.87
Market Cap	452K
PE Ratio	None
Target Price	14.5
Dividend Yield	None

ABOUT

BioLineRx Ltd

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

YP2A.F · BioLineRx Ltd

-

BioLineRx Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest BioLineRx Ltd using a moving average strategy